Laboratory Corp of America Holdings (LH)

$257.35 +2.27 (0.89%)
Market Cap 20.92B
Revenue (ttm) 13.95B
Net Income (ttm) 876.50M
EPS (ttm) N/A
PE Ratio 15.08
Forward PE 14.13
Profit Margin 6.28%
Debt to Equity Ratio 0.67
Volume 732,300
Avg Vol 635,722
Day's Range N/A - N/A
Shares Out 82.00M
Stochastic %K 50%
Beta 0.91
Analysts Strong Sell
Price Target $311.47

Company Profile

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 336 229 1127
Address:
358 South Main Street, Burlington, United States
BillionerOfKing
BillionerOfKing May. 8 at 5:19 AM
$LH Current Stock Price: $258.04 Contracts to trade: $260.0 LH May 15 2026 Call Entry: $2.71 Exit: $4.20 ROI: 55% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing May. 6 at 10:57 PM
$LH Current Stock Price: $256.92 Contracts to trade: $260.0 LH May 15 2026 Call Entry: $2.65 Exit: $4.73 ROI: 79% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CapitalMonk
CapitalMonk May. 6 at 6:45 PM
$LH Price: $257.48 (+0.13%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.23% RSI: 37.3 | Momentum: Moderate Volume: -26.1% vs avg Volatility: 1.54% Support: $248.59 | Resistance: $279.71 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
SuperGreenToday
SuperGreenToday May. 4 at 5:33 PM
$LH Share Price: $252.43 Contract Selected: Nov 20, 2026 $250 Calls Buy Zone: $19.38 – $23.94 Target Zone: $31.22 – $38.15 Potential Upside: 52% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TheContessa
TheContessa May. 4 at 12:11 AM
$LH Based on 10 Wall Street analysts offering 12 month price targets for Labcorp Holdings in the last 3 months the average price target is $309.63 with a high forecast of $334.00 and a low forecast of $290.00. The average price target represents a nice gain. Tune out the FUD. ✅📶
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 30 at 11:03 AM
$LH Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $3.37 up 32.68% YoY • Reported revenue of $3.54B up 5.75% YoY • Labcorp raised full-year 2026 enterprise revenue guidance to 5.0% to 6.1% and adjusted EPS guidance to a range of $17.70 to $18.35, reflecting an increase of 13 cents at the midpoint.
2 · Reply
prismmarketview
prismmarketview Apr. 15 at 5:28 PM
$LH announced the launch of its FDA‑cleared Fentanyl Urine Visual Test, the first rapid fentanyl test of its kind manufactured in the U.S. It delivers results in ~10 minutes for use in ERs, hospitals and clinics—critical when you’re triaging suspected exposure/overdose. https://prismmarketview.com/labcorp-unveils-10-minute-fda-cleared-fentanyl-test-for-emergency-settings/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 8 at 10:30 PM
$LH RSI: 62.73, MACD: -0.2283 Vol: 3.96, MA20: 267.59, MA50: 273.82 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Mar. 4 at 1:35 PM
$LH up 10.2% in the past year, but are macro headwinds a threat? ⚠️ 🔍 Strategic test expansion in neurology, oncology, & autoimmune disease 🚀 🌍 Currency fluctuations & geopolitical tensions could dent overseas revenues Discover the full growth vs. risk analysis here 👉 https://www.zacks.com/stock/news/2878452/is-this-the-right-time-to-hold-labcorp-stock-in-your-portfolio?cid=sm-stocktwits-2-2878452-body-35856&ADID=SYND_STOCKTWITS_TWEET_2_2878452_BODY_35856
0 · Reply
ZacksResearch
ZacksResearch Mar. 4 at 12:35 PM
$LH is pushing for growth — but macro and currency risks aren’t going away ⚠️ The company is eyeing expansion through specialty test growth, acquisitions, and LaunchPad savings initiatives. Solid internal levers… yet currency headwinds and broader macro pressures are still clouding the outlook. Is this a smart long-term setup or a near-term grind? Full breakdown here 👉 https://www.zacks.com/stock/news/2878452/is-this-the-right-time-to-hold-labcorp-stock-in-your-portfolio?cid=sm-stocktwits-2-2878452-teaser-35851&ADID=SYND_STOCKTWITS_TWEET_2_2878452_TEASER_35851
0 · Reply
Latest News on LH
Labcorp, Epic expand collaboration

2026-05-12T13:09:47.000Z - 23 hours ago

Labcorp, Epic expand collaboration

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

May 12, 2026, 7:00 AM EDT - 1 day ago

Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems

Labcorp price target raised to $334 from $332 at Baird

2026-05-01T14:38:36.000Z - 11 days ago

Labcorp price target raised to $334 from $332 at Baird

Labcorp reports Q1 adjusted EPS $4.25, consensus $4.12

2026-04-30T13:17:12.000Z - 12 days ago

Labcorp reports Q1 adjusted EPS $4.25, consensus $4.12

Labcorp raises FY26 adjusted EPS view to $17.70-$18.35 from $17.55-$18.25

2026-04-30T13:11:54.000Z - 12 days ago

Labcorp raises FY26 adjusted EPS view to $17.70-$18.35 from $17.55-$18.25

Labcorp Holdings Earnings Call Transcript: Q1 2026

Apr 30, 2026, 9:00 AM EDT - 12 days ago

Labcorp Holdings Earnings Call Transcript: Q1 2026

Labcorp raises full-year forecasts on steady diagnostics demand

Apr 30, 2026, 8:04 AM EDT - 13 days ago

Labcorp raises full-year forecasts on steady diagnostics demand

Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

Apr 30, 2026, 6:50 AM EDT - 13 days ago

Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance

Labcorp announces availability of Agilent’s PD-L1 IHC 22C3 pharmDx

2026-04-22T11:31:54.000Z - 21 days ago

Labcorp announces availability of Agilent’s PD-L1 IHC 22C3 pharmDx

A MRK

Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®

Apr 22, 2026, 7:00 AM EDT - 21 days ago

Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®

d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth

Apr 21, 2026, 5:44 AM EDT - 22 days ago

d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth

Labcorp announces launch of Labcorp Fentanyl Urine Visual Test

2026-04-15T11:03:55.000Z - 4 weeks ago

Labcorp announces launch of Labcorp Fentanyl Urine Visual Test

Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes

Apr 15, 2026, 7:00 AM EDT - 4 weeks ago

Labcorp Launches FDA-Cleared Fentanyl Test Delivering Results in 10 Minutes

Labcorp launches new AI-powered real-world data platform with AWS

2026-04-14T11:22:25.000Z - 4 weeks ago

Labcorp launches new AI-powered real-world data platform with AWS

AMZN

Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research

Apr 14, 2026, 7:00 AM EDT - 4 weeks ago

Labcorp Introduces AI-Powered Real-World Data Platform with AWS and Datavant to Accelerate Alzheimer's Research

Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide

Apr 13, 2026, 8:30 AM EDT - 4 weeks ago

Children's Hospital of Philadelphia and Labcorp Announce a Collaboration to Accelerate Access to Advanced Pediatric Diagnostics Nationwide

Labcorp Declares Quarterly Dividend

Apr 9, 2026, 6:50 AM EDT - 4 weeks ago

Labcorp Declares Quarterly Dividend

Labcorp price target raised to $300 from $280 at Evercore ISI

2026-04-08T13:16:59.000Z - 4 weeks ago

Labcorp price target raised to $300 from $280 at Evercore ISI

Labcorp to Announce First Quarter Financial Results on April 30, 2026

Mar 31, 2026, 4:15 PM EDT - 6 weeks ago

Labcorp to Announce First Quarter Financial Results on April 30, 2026

Labcorp, Illumina expand collaboration to broaden access to oncology testing

2026-03-18T13:21:59.000Z - 7 weeks ago

Labcorp, Illumina expand collaboration to broaden access to oncology testing

ILMN

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Mar 18, 2026, 9:15 AM EDT - 7 weeks ago

Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

ILMN

Labcorp price target raised to $300 from $270 at Piper Sandler

2026-02-24T11:47:26.000Z - 2 months ago

Labcorp price target raised to $300 from $270 at Piper Sandler

Labcorp collaborates with PathAI to deploy FDA-cleared pathology platform

2026-02-23T12:11:37.000Z - 2 months ago

Labcorp collaborates with PathAI to deploy FDA-cleared pathology platform

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

Feb 23, 2026, 7:00 AM EST - 2 months ago

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

Labcorp price target raised to $326 from $313 at Baird

2026-02-18T12:50:42.000Z - 2 months ago

Labcorp price target raised to $326 from $313 at Baird

Labcorp price target raised to $330 from $319 at JPMorgan

2026-02-18T12:40:25.000Z - 3 months ago

Labcorp price target raised to $330 from $319 at JPMorgan

Labcorp guidance ‘should be well received,’ says Morgan Stanley

2026-02-17T19:20:37.000Z - 3 months ago

Labcorp guidance ‘should be well received,’ says Morgan Stanley

DGX

Labcorp Holdings Earnings Call Transcript: Q4 2025

Feb 17, 2026, 9:00 AM EST - 3 months ago

Labcorp Holdings Earnings Call Transcript: Q4 2025

Labcorp forecasts upbeat annual profit on strong demand for diagnostic products

Feb 17, 2026, 7:59 AM EST - 3 months ago

Labcorp forecasts upbeat annual profit on strong demand for diagnostic products

Labcorp reports Q4 adjusted EPS $4.07, consensus $3.94

2026-02-17T12:26:12.000Z - 3 months ago

Labcorp reports Q4 adjusted EPS $4.07, consensus $3.94

Labcorp Announces 2025 Fourth Quarter and Full Year Results

Feb 17, 2026, 6:50 AM EST - 3 months ago

Labcorp Announces 2025 Fourth Quarter and Full Year Results

Notable companies reporting before Tuesday’s open

2026-02-13T18:51:10.000Z - 3 months ago

Notable companies reporting before Tuesday’s open

LDOS MDT

Labcorp announces availability of Elecsys pTau-181 test

2026-02-11T12:13:18.000Z - 3 months ago

Labcorp announces availability of Elecsys pTau-181 test

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

Feb 11, 2026, 7:00 AM EST - 3 months ago

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

Labcorp Appoints John H. Sampson, M.D.

Feb 9, 2026, 8:30 AM EST - 3 months ago

Labcorp Appoints John H. Sampson, M.D.

Labcorp price target raised to $319 from $317 at JPMorgan

2026-02-06T12:21:34.000Z - 3 months ago

Labcorp price target raised to $319 from $317 at JPMorgan

Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

Jan 15, 2026, 4:15 PM EST - 4 months ago

Labcorp to Announce Fourth Quarter Financial Results on February 17, 2026

Labcorp Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 7:30 PM EST - 4 months ago

Labcorp Holdings Transcript: 44th Annual J.P. Morgan Healthcare Conference

Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

Jan 13, 2026, 7:00 AM EST - 4 months ago

Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk

Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs

Jan 8, 2026, 9:00 AM EST - 4 months ago

Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs

NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp

Jan 8, 2026, 8:30 AM EST - 4 months ago

NAMSA Announces Strategic Acquisition of Select Assets of the Early Development Medical Device Testing Business of Labcorp

Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference

Dec 30, 2025, 4:15 PM EST - 4 months ago

Labcorp to Speak at the 44th Annual J.P. Morgan Healthcare Conference

Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks

Dec 15, 2025, 10:00 AM EST - 5 months ago

Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks

Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp

Dec 2, 2025, 4:15 PM EST - 5 months ago

Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp

CYH

Labcorp Appoints Victor Bulto to Board of Directors

Nov 24, 2025, 8:30 AM EST - 6 months ago

Labcorp Appoints Victor Bulto to Board of Directors

Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research

Nov 19, 2025, 7:04 AM EST - 6 months ago

Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research

Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research

Nov 17, 2025, 9:00 AM EST - 6 months ago

Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research

Labcorp Holdings Earnings Call Transcript: Q3 2025

Oct 28, 2025, 9:00 AM EDT - 7 months ago

Labcorp Holdings Earnings Call Transcript: Q3 2025

Labcorp lifts annual profit forecast on strong diagnostic test demand

Oct 28, 2025, 6:52 AM EDT - 7 months ago

Labcorp lifts annual profit forecast on strong diagnostic test demand

Labcorp Announces 2025 Third Quarter Results

Oct 28, 2025, 6:50 AM EDT - 7 months ago

Labcorp Announces 2025 Third Quarter Results

Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings

Oct 23, 2025, 7:00 AM EDT - 7 months ago

Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings

Praia Health, Providence, and Labcorp Collaborate to Transform Patient Engagement and Lab Order Adherence

Oct 20, 2025, 9:00 AM EDT - 7 months ago

Praia Health, Providence, and Labcorp Collaborate to Transform Patient Engagement and Lab Order Adherence

Labcorp Announces Collaboration with Roche to Advance Digital Pathology Capabilities

Sep 30, 2025, 7:00 AM EDT - 8 months ago

Labcorp Announces Collaboration with Roche to Advance Digital Pathology Capabilities

Labcorp to Announce Third Quarter Financial Results on October 28, 2025

Sep 25, 2025, 4:15 PM EDT - 8 months ago

Labcorp to Announce Third Quarter Financial Results on October 28, 2025

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

Sep 15, 2025, 8:30 AM EDT - 8 months ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

OPK

Labcorp Holdings Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 7:45 AM EDT - 8 months ago

Labcorp Holdings Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Labcorp to Speak at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 27, 2025, 4:15 PM EDT - 9 months ago

Labcorp to Speak at the Morgan Stanley 23rd Annual Global Healthcare Conference

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

Aug 18, 2025, 7:00 AM EDT - 9 months ago

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

Jul 30, 2025, 7:12 AM EDT - 10 months ago

Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

Labcorp Achieves IVDR CE-Marking for PGDx elio™ tissue complete in the EU

Jul 29, 2025, 7:00 AM EDT - 10 months ago

Labcorp Achieves IVDR CE-Marking for PGDx elio™ tissue complete in the EU

Labcorp Holdings Earnings Call Transcript: Q2 2025

Jul 24, 2025, 9:00 AM EDT - 10 months ago

Labcorp Holdings Earnings Call Transcript: Q2 2025

Labcorp raises annual profit forecast on strong diagnostic testing demand

Jul 24, 2025, 7:00 AM EDT - 10 months ago

Labcorp raises annual profit forecast on strong diagnostic testing demand

Labcorp Announces 2025 Second Quarter Results

Jul 24, 2025, 6:50 AM EDT - 10 months ago

Labcorp Announces 2025 Second Quarter Results

Community Health Systems Announces Definitive Agreement to Sell Select Outreach Laboratory Assets to Labcorp

Jul 22, 2025, 4:15 PM EDT - 10 months ago

Community Health Systems Announces Definitive Agreement to Sell Select Outreach Laboratory Assets to Labcorp

CYH

Labcorp to Announce Second Quarter Financial Results on July 24, 2025

Jun 26, 2025, 4:10 PM EDT - 11 months ago

Labcorp to Announce Second Quarter Financial Results on July 24, 2025

ASU, Labcorp, and InStride announce first-of-its-kind diagnostics industry partnership that tackles critical healthcare workforce shortage

Jun 2, 2025, 7:00 AM EDT - 1 year ago

ASU, Labcorp, and InStride announce first-of-its-kind diagnostics industry partnership that tackles critical healthcare workforce shortage

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

May 30, 2025, 7:00 AM EDT - 1 year ago

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

Labcorp Holdings Transcript: AGM 2025

May 15, 2025, 9:00 AM EDT - 1 year ago

Labcorp Holdings Transcript: AGM 2025

Labcorp to Webcast Its Annual Meeting of Shareholders May 15

May 8, 2025, 4:15 PM EDT - 1 year ago

Labcorp to Webcast Its Annual Meeting of Shareholders May 15

Labcorp Holdings Earnings Call Transcript: Q1 2025

Apr 29, 2025, 9:00 AM EDT - 1 year ago

Labcorp Holdings Earnings Call Transcript: Q1 2025

Labcorp beats quarterly profit estimate on diagnostic test demand

Apr 29, 2025, 6:56 AM EDT - 1 year ago

Labcorp beats quarterly profit estimate on diagnostic test demand

Labcorp Announces 2025 First Quarter Results

Apr 29, 2025, 6:50 AM EDT - 1 year ago

Labcorp Announces 2025 First Quarter Results

Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

Apr 23, 2025, 7:00 AM EDT - 1 year ago

Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics

Apr 11, 2025, 5:32 AM EDT - 1 year ago

Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics

Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Apr 2, 2025, 7:00 AM EDT - 1 year ago

Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

Apr 1, 2025, 8:32 AM EDT - 1 year ago

Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

BillionerOfKing
BillionerOfKing May. 8 at 5:19 AM
$LH Current Stock Price: $258.04 Contracts to trade: $260.0 LH May 15 2026 Call Entry: $2.71 Exit: $4.20 ROI: 55% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BillionerOfKing
BillionerOfKing May. 6 at 10:57 PM
$LH Current Stock Price: $256.92 Contracts to trade: $260.0 LH May 15 2026 Call Entry: $2.65 Exit: $4.73 ROI: 79% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CapitalMonk
CapitalMonk May. 6 at 6:45 PM
$LH Price: $257.48 (+0.13%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.23% RSI: 37.3 | Momentum: Moderate Volume: -26.1% vs avg Volatility: 1.54% Support: $248.59 | Resistance: $279.71 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
SuperGreenToday
SuperGreenToday May. 4 at 5:33 PM
$LH Share Price: $252.43 Contract Selected: Nov 20, 2026 $250 Calls Buy Zone: $19.38 – $23.94 Target Zone: $31.22 – $38.15 Potential Upside: 52% ROI Time to Expiration: 199 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
TheContessa
TheContessa May. 4 at 12:11 AM
$LH Based on 10 Wall Street analysts offering 12 month price targets for Labcorp Holdings in the last 3 months the average price target is $309.63 with a high forecast of $334.00 and a low forecast of $290.00. The average price target represents a nice gain. Tune out the FUD. ✅📶
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 30 at 11:03 AM
$LH Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $3.37 up 32.68% YoY • Reported revenue of $3.54B up 5.75% YoY • Labcorp raised full-year 2026 enterprise revenue guidance to 5.0% to 6.1% and adjusted EPS guidance to a range of $17.70 to $18.35, reflecting an increase of 13 cents at the midpoint.
2 · Reply
prismmarketview
prismmarketview Apr. 15 at 5:28 PM
$LH announced the launch of its FDA‑cleared Fentanyl Urine Visual Test, the first rapid fentanyl test of its kind manufactured in the U.S. It delivers results in ~10 minutes for use in ERs, hospitals and clinics—critical when you’re triaging suspected exposure/overdose. https://prismmarketview.com/labcorp-unveils-10-minute-fda-cleared-fentanyl-test-for-emergency-settings/
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 8 at 10:30 PM
$LH RSI: 62.73, MACD: -0.2283 Vol: 3.96, MA20: 267.59, MA50: 273.82 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ZacksResearch
ZacksResearch Mar. 4 at 1:35 PM
$LH up 10.2% in the past year, but are macro headwinds a threat? ⚠️ 🔍 Strategic test expansion in neurology, oncology, & autoimmune disease 🚀 🌍 Currency fluctuations & geopolitical tensions could dent overseas revenues Discover the full growth vs. risk analysis here 👉 https://www.zacks.com/stock/news/2878452/is-this-the-right-time-to-hold-labcorp-stock-in-your-portfolio?cid=sm-stocktwits-2-2878452-body-35856&ADID=SYND_STOCKTWITS_TWEET_2_2878452_BODY_35856
0 · Reply
ZacksResearch
ZacksResearch Mar. 4 at 12:35 PM
$LH is pushing for growth — but macro and currency risks aren’t going away ⚠️ The company is eyeing expansion through specialty test growth, acquisitions, and LaunchPad savings initiatives. Solid internal levers… yet currency headwinds and broader macro pressures are still clouding the outlook. Is this a smart long-term setup or a near-term grind? Full breakdown here 👉 https://www.zacks.com/stock/news/2878452/is-this-the-right-time-to-hold-labcorp-stock-in-your-portfolio?cid=sm-stocktwits-2-2878452-teaser-35851&ADID=SYND_STOCKTWITS_TWEET_2_2878452_TEASER_35851
0 · Reply
smartkarma
smartkarma Feb. 25 at 9:02 PM
$LH | LH US - Labcorp's BIGGEST Pressure Point Is 13.5% Early Development Decline "Labcorp Holdings reported strong financial performance for the fourth quarter and full year 2025, with notable advancements across various..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/lh-us-labcorp-s-biggest-pressure-point-is-13-5-early-development-decline
0 · Reply
IN0V8
IN0V8 Feb. 25 at 7:02 PM
$LH 2/24 Piper Sandler raises target price to $300 from $270
0 · Reply
EarningsCentral
EarningsCentral Feb. 20 at 3:45 AM
$LH Q4 2025 Earnings | Record Cash Flow, FDA Cleared Alzheimer’s Test & Future https://youtu.be/NgDtYaGO8nw
0 · Reply
Nosh
Nosh Feb. 20 at 2:45 AM
$LH Nice recovery...does it hold.
0 · Reply
ZacksResearch
ZacksResearch Feb. 17 at 7:10 PM
$LH beats on earnings… and the stock still drops? 👀 Q4 EPS jumped 18% and topped estimates, but a revenue miss is stealing the spotlight — and shares are sliding in pre-market as investors react cautiously. Is this a buy-the-dip setup or a warning sign? Get the full breakdown 👉 https://www.zacks.com/stock/news/2870557/labcorp-q4-earnings-beat-revenues-miss-stock-down-in-pre-market?cid=sm-stocktwits-2-2870557-teaser-33906&ADID=SYND_STOCKTWITS_TWEET_2_2870557_TEASER_33906
0 · Reply
1986iamwallstreet
1986iamwallstreet Feb. 17 at 2:35 PM
$LH sell the bid in full Play 🩸🩸🩸🩸🩸🩸
0 · Reply
1986iamwallstreet
1986iamwallstreet Feb. 17 at 2:16 PM
$LH Revenue Growth Slowing FY 2025 Revenue Growth: 7.2% 2026 Enterprise Guidance: 4.7% – 6.0% Midpoint growth decelerates to ~5.4%. 🩸🩸🩸🩸🩸🩸
0 · Reply
1986iamwallstreet
1986iamwallstreet Feb. 17 at 2:16 PM
$LH High Debt Load Total Debt: $5.58B Cash: $532M Net Debt ≈ $5.05B In a rising-rate or tighter credit environment, that leverage matters. Interest expense already $224M annually. 🩸🩸🩸🩸🩸🩸🩸🩸🩸
0 · Reply
1986iamwallstreet
1986iamwallstreet Feb. 17 at 2:15 PM
$LH Diagnostics Volume vs Price Mix Requisition volume growth: Organic volume only 1.1% Price/mix 3.0% Volume growth is modest. Pricing is doing more of the work. If reimbursement tightens, that pricing leverage could reverse. 🩸🩸🩸🩸🩸🩸🩸🩸🩸
0 · Reply